Natural Product (NP) Details
General Information of the NP (ID: NP3528) | |||||
---|---|---|---|---|---|
Name |
Magnolol
|
||||
Synonyms |
Magnolol; 528-43-8; 5,5'-Diallyl-[1,1'-biphenyl]-2,2'-diol; 5,5'-Diallyl-2,2'-biphenyldiol; 2,2'-Bichavicol; 5,5'-Diallyl-2,2'-dihydroxybiphenyl; NSC 293099; Dehydrodichavicol; UNII-001E35HGVF; 4-allyl-2-(5-allyl-2-hydroxy-phenyl)phenol; MFCD00016658; MLS001048917; 001E35HGVF; 2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenol; CHEBI:6643; 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol; 5,5'-Diallylbiphenyl-2,2'-diol; [1,1'-Biphenyl]-2,2'-diol, 5,5'-di-2-propenyl-; SMR000387108; (1,1'-Biphenyl)-2,2'-diol, 5,5'-di-2-propenyl-; 2'-Bichavicol; SR-01000758206; Kopnolia; HSDB 7686; Magnolol,(S); PubChem19035; UPCMLD-DP037; cid_72300; SCHEMBL132477; REGID_for_CID_72300; CHEMBL180920; ZINC1645; DTXSID0044076; UPCMLD-DP037:001; BDBM78304; HMS2269N09; HMS3651O18; AMY40661; BCP28276; HY-N0163; AC-931; BBL027818; CM0085; NSC293099; s2321; STK801955; AKOS005266409; ACN-035415; CCG-208588; CS-5021; DS-1284; MCULE-1351244567; NSC-293099; SMP2_000086; Magnolol, >=95% (HPLC), from plant; NCGC00161609-01; NCGC00161609-02; AK-72952; O906; SY016075; AB0016717; D3971; FT-0628104; N1359; SW219728-1; 5,5`-Diallyl-[1,1`-biphenyl]-2,2`-diol; A10551; C10651; J10186; S-2836; 528M438; 5,5'-Di-2-propenyl-[1,1'-biphenyl]-2,2'-diol; Q-100598; Q6732002; SR-01000758206-3; SR-01000758206-4; BRD-K26168087-001-01-4; Magnolol, European Pharmacopoeia (EP) Reference Standard; [1,1'-Biphenyl]-2,2'-diol, 5,5'-di-2-propen-1-yl-; 2-(2-oxidanyl-5-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; 5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2,2'-diol; 2-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol; 5,5 inverted exclamation mark -Diallyl-2,2 inverted exclamation mark -biphenyldiol
Click to Show/Hide
|
||||
Species Origin | Magnolia officinalis ... | Click to Show/Hide | |||
Magnolia officinalis | |||||
Disease | Cancer cachexia [ICD-11: MG20] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C18H18O2
|
||||
PubChem CID | |||||
Canonical SMILES |
C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O
|
||||
InChI |
1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2
|
||||
InChIKey |
VVOAZFWZEDHOOU-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 528-43-8
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Caki | Clear cell renal cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Magnolol enhanced TRAIL-induced apoptosis via ATF4-dependent DR5 upregulation and downregulation of c-FLIP and Mcl-1 proteins. | |||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | ||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC. | |||||
Azoles | Trypanosomiasis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Candida albicans | Microorganism model | Candida albicans | |||
Experimental
Result(s) |
Magnolol synergizes with azoles for targeting of C. albicans by inducing a higher intracellular content of antifungals, by tapping into the competitive effect of ABC transporter Cdr1p substrates, and enhancing the effect by targeting of the ergosterol biosynthesis pathway. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
MG could prevent the development and progression of mucositis induced by oxaliplatin through multipathway. | |||||
γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | ||
CT26 | CVCL_7254 | Mouse colon adenocarcinoma | Mus musculus | |||
Experimental
Result(s) |
Magnolol attenuates cisplatin-induced muscle wasting by M2c macrophage activation. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Interleukin-1 beta (IL1B) | Molecule Info | [7] | |
Matrix metalloproteinase-9 (MMP-9) | Molecule Info | [7] | ||
Protein kinase B alpha (AKT1) | Molecule Info | [3] | ||
Tumor necrosis factor (TNF) | Molecule Info | [7] | ||
Tyrosine kinase receptor Erbb2 (HER2) | Molecule Info | [8] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Sphingolipid signaling pathway | |||
11 | mTOR signaling pathway | |||
12 | PI3K-Akt signaling pathway | |||
13 | AMPK signaling pathway | |||
14 | Apoptosis | |||
15 | Adrenergic signaling in cardiomyocytes | |||
16 | VEGF signaling pathway | |||
17 | Osteoclast differentiation | |||
18 | Focal adhesion | |||
19 | Tight junction | |||
20 | Signaling pathways regulating pluripotency of stem cells | |||
21 | Platelet activation | |||
22 | Toll-like receptor signaling pathway | |||
23 | Jak-STAT signaling pathway | |||
24 | T cell receptor signaling pathway | |||
25 | B cell receptor signaling pathway | |||
26 | Fc epsilon RI signaling pathway | |||
27 | Fc gamma R-mediated phagocytosis | |||
28 | TNF signaling pathway | |||
29 | Neurotrophin signaling pathway | |||
30 | Cholinergic synapse | |||
31 | Dopaminergic synapse | |||
32 | Insulin signaling pathway | |||
33 | Progesterone-mediated oocyte maturation | |||
34 | Estrogen signaling pathway | |||
35 | Prolactin signaling pathway | |||
36 | Thyroid hormone signaling pathway | |||
37 | Adipocytokine signaling pathway | |||
38 | Glucagon signaling pathway | |||
39 | Regulation of lipolysis in adipocytes | |||
40 | Non-alcoholic fatty liver disease (NAFLD) | |||
41 | Carbohydrate digestion and absorption | |||
42 | Chagas disease (American trypanosomiasis) | |||
43 | Toxoplasmosis | |||
44 | Tuberculosis | |||
45 | Hepatitis C | |||
46 | Hepatitis B | |||
47 | Measles | |||
48 | Influenza A | |||
49 | HTLV-I infection | |||
50 | Epstein-Barr virus infection | |||
51 | Pathways in cancer | |||
52 | Proteoglycans in cancer | |||
53 | Colorectal cancer | |||
54 | Renal cell carcinoma | |||
55 | Pancreatic cancer | |||
56 | Endometrial cancer | |||
57 | Glioma | |||
58 | Prostate cancer | |||
59 | Melanoma | |||
60 | Chronic myeloid leukemia | |||
61 | Acute myeloid leukemia | |||
62 | Small cell lung cancer | |||
63 | Non-small cell lung cancer | |||
64 | Central carbon metabolism in cancer | |||
65 | Choline metabolism in cancer | |||
66 | Cytokine-cytokine receptor interaction | |||
67 | NF-kappa B signaling pathway | |||
68 | TGF-beta signaling pathway | |||
69 | Antigen processing and presentation | |||
70 | NOD-like receptor signaling pathway | |||
71 | RIG-I-like receptor signaling pathway | |||
72 | Hematopoietic cell lineage | |||
73 | Natural killer cell mediated cytotoxicity | |||
74 | Type II diabetes mellitus | |||
75 | Type I diabetes mellitus | |||
76 | Alzheimer's disease | |||
77 | Amyotrophic lateral sclerosis (ALS) | |||
78 | Pertussis | |||
79 | Legionellosis | |||
80 | Leishmaniasis | |||
81 | African trypanosomiasis | |||
82 | Malaria | |||
83 | Amoebiasis | |||
84 | Herpes simplex infection | |||
85 | Asthma | |||
86 | Inflammatory bowel disease (IBD) | |||
87 | Systemic lupus erythematosus | |||
88 | Rheumatoid arthritis | |||
89 | Allograft rejection | |||
90 | Graft-versus-host disease | |||
91 | Hypertrophic cardiomyopathy (HCM) | |||
92 | Dilated cardiomyopathy | |||
93 | Calcium signaling pathway | |||
94 | Adherens junction | |||
95 | MicroRNAs in cancer | |||
96 | Bladder cancer | |||
97 | Leukocyte transendothelial migration | |||
98 | Transcriptional misregulation in cancer | |||
99 | Cytosolic DNA-sensing pathway | |||
100 | Inflammatory mediator regulation of TRP channels | |||
101 | Prion diseases | |||
102 | Salmonella infection | |||
NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
3 | IL2 Signaling Pathway | |||
4 | IL3 Signaling Pathway | |||
5 | IL4 Signaling Pathway | |||
6 | Leptin Signaling Pathway | |||
7 | RANKL Signaling Pathway | |||
8 | IL1 Signaling Pathway | |||
9 | ID Signaling Pathway | |||
10 | TWEAK Signaling Pathway | |||
11 | TNFalpha Signaling Pathway | |||
12 | IL5 Signaling Pathway | |||
13 | TGF_beta_Receptor Signaling Pathway | |||
14 | Wnt Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | Apoptosis signaling pathway | |||
3 | EGF receptor signaling pathway | |||
4 | Endothelin signaling pathway | |||
5 | FGF signaling pathway | |||
6 | Huntington disease | |||
7 | Hypoxia response via HIF activation | |||
8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
9 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
10 | Interleukin signaling pathway | |||
11 | PI3 kinase pathway | |||
12 | T cell activation | |||
13 | VEGF signaling pathway | |||
14 | p53 pathway | |||
15 | Ras Pathway | |||
16 | p53 pathway by glucose deprivation | |||
17 | p53 pathway feedback loops 2 | |||
18 | CCKR signaling map ST | |||
19 | Wnt signaling pathway | |||
20 | Cadherin signaling pathway | |||
21 | Alzheimer disease-presenilin pathway | |||
22 | Plasminogen activating cascade | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
4 | Insulin Signalling | |||
5 | Leucine Stimulation on Insulin Signaling | |||
6 | Phosphatidylinositol Phosphate Metabolism | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Fc-epsilon receptor I signaling in mast cells | |||
3 | Endothelins | |||
4 | BCR signaling pathway | |||
5 | LPA receptor mediated events | |||
6 | Insulin Pathway | |||
7 | IL4-mediated signaling events | |||
8 | TCR signaling in naï | |||
9 | ||||
10 | Plasma membrane estrogen receptor signaling | |||
11 | CD40/CD40L signaling | |||
12 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
13 | Signaling events mediated by PTP1B | |||
14 | S1P3 pathway | |||
15 | Coregulation of Androgen receptor activity | |||
16 | Reelin signaling pathway | |||
17 | Integrin-linked kinase signaling | |||
18 | TCR signaling in naï | |||
19 | ||||
20 | Angiopoietin receptor Tie2-mediated signaling | |||
21 | FAS (CD95) signaling pathway | |||
22 | Thromboxane A2 receptor signaling | |||
23 | Regulation of Telomerase | |||
24 | FOXA2 and FOXA3 transcription factor networks | |||
25 | Glucocorticoid receptor regulatory network | |||
26 | mTOR signaling pathway | |||
27 | CXCR4-mediated signaling events | |||
28 | IGF1 pathway | |||
29 | FoxO family signaling | |||
30 | IL2 signaling events mediated by PI3K | |||
31 | Ceramide signaling pathway | |||
32 | p75(NTR)-mediated signaling | |||
33 | E-cadherin signaling in the nascent adherens junction | |||
34 | amb2 Integrin signaling | |||
35 | Integrins in angiogenesis | |||
36 | IFN-gamma pathway | |||
37 | ErbB1 downstream signaling | |||
38 | ErbB2/ErbB3 signaling events | |||
39 | IL6-mediated signaling events | |||
40 | E-cadherin signaling in keratinocytes | |||
41 | Nephrin/Neph1 signaling in the kidney podocyte | |||
42 | Retinoic acid receptors-mediated signaling | |||
43 | IL8- and CXCR2-mediated signaling events | |||
44 | Signaling events mediated by the Hedgehog family | |||
45 | Nongenotropic Androgen signaling | |||
46 | Hedgehog signaling events mediated by Gli proteins | |||
47 | Caspase Cascade in Apoptosis | |||
48 | CXCR3-mediated signaling events | |||
49 | VEGFR1 specific signals | |||
50 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
51 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
52 | a6b1 and a6b4 Integrin signaling | |||
53 | Aurora A signaling | |||
54 | Insulin-mediated glucose transport | |||
55 | Class I PI3K signaling events mediated by Akt | |||
56 | IL8- and CXCR1-mediated signaling events | |||
57 | HIF-1-alpha transcription factor network | |||
58 | p53 pathway | |||
59 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
60 | VEGFR3 signaling in lymphatic endothelium | |||
61 | FGF signaling pathway | |||
62 | IL27-mediated signaling events | |||
63 | Canonical NF-kappaB pathway | |||
64 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
65 | Signaling events mediated by HDAC Class I | |||
66 | TNF receptor signaling pathway | |||
67 | RXR and RAR heterodimerization with other nuclear receptor | |||
68 | IL23-mediated signaling events | |||
69 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
70 | Cellular roles of Anthrax toxin | |||
71 | Downstream signaling in naï | |||
72 | ErbB4 signaling events | |||
73 | ErbB receptor signaling network | |||
74 | Validated targets of C-MYC transcriptional repression | |||
75 | Osteopontin-mediated events | |||
76 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
77 | Validated targets of C-MYC transcriptional activation | |||
78 | Syndecan-4-mediated signaling events | |||
79 | AP-1 transcription factor network | |||
80 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
81 | Syndecan-1-mediated signaling events | |||
82 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
83 | IL12-mediated signaling events | |||
84 | IL1-mediated signaling events | |||
Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
2 | GPVI-mediated activation cascade | |||
3 | PIP3 activates AKT signaling | |||
4 | Translocation of GLUT4 to the plasma membrane | |||
5 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
6 | AKT phosphorylates targets in the cytosol | |||
7 | AKT phosphorylates targets in the nucleus | |||
8 | Negative regulation of the PI3K/AKT network | |||
9 | eNOS activation | |||
10 | AKT-mediated inactivation of FOXO1A | |||
11 | Integrin alphaIIb beta3 signaling | |||
12 | Deactivation of the beta-catenin transactivating complex | |||
13 | CD28 dependent PI3K/Akt signaling | |||
14 | CTLA4 inhibitory signaling | |||
15 | G beta:gamma signalling through PI3Kgamma | |||
16 | KSRP (KHSRP) binds and destabilizes mRNA | |||
17 | VEGFR2 mediated vascular permeability | |||
18 | TP53 Regulates Metabolic Genes | |||
19 | Constitutive Signaling by AKT1 E17K in Cancer | |||
20 | Transcriptional regulation of white adipocyte differentiation | |||
21 | TNFR1-induced proapoptotic signaling | |||
22 | Regulation of TNFR1 signaling | |||
23 | TNFR1-induced NFkappaB signaling pathway | |||
24 | TNFR1-mediated ceramide production | |||
25 | TNFR2 non-canonical NF-kB pathway | |||
26 | TNF signaling | |||
27 | SHC1 events in ERBB2 signaling | |||
28 | PLCG1 events in ERBB2 signaling | |||
29 | GRB2 events in ERBB2 signaling | |||
30 | PI3K events in ERBB2 signaling | |||
31 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
32 | Sema4D induced cell migration and growth-cone collapse | |||
33 | RAF/MAP kinase cascade | |||
34 | Collagen degradation | |||
35 | Degradation of the extracellular matrix | |||
36 | Activation of Matrix Metalloproteinases | |||
37 | Assembly of collagen fibrils and other multimeric structures | |||
38 | EPH-ephrin mediated repulsion of cells | |||
39 | Interleukin-1 signaling | |||
40 | Interleukin-1 processing | |||
41 | CLEC7A/inflammasome pathway | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | DNA Damage Response (only ATM dependent) | |||
3 | TCR Signaling Pathway | |||
4 | Notch Signaling Pathway | |||
5 | EPO Receptor Signaling | |||
6 | IL-2 Signaling Pathway | |||
7 | Insulin Signaling | |||
8 | Endochondral Ossification | |||
9 | EGF/EGFR Signaling Pathway | |||
10 | IL-4 Signaling Pathway | |||
11 | TGF beta Signaling Pathway | |||
12 | IL-6 signaling pathway | |||
13 | Wnt Signaling Pathway Netpath | |||
14 | Copper homeostasis | |||
15 | Extracellular vesicle-mediated signaling in recipient cells | |||
16 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
17 | IL-3 Signaling Pathway | |||
18 | Cardiac Hypertrophic Response | |||
19 | Translocation of GLUT4 to the Plasma Membrane | |||
20 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
21 | PIP3 activates AKT signaling | |||
22 | Signal Transduction of S1P Receptor | |||
23 | T-Cell Receptor and Co-stimulatory Signaling | |||
24 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
25 | Apoptosis | |||
26 | Alpha 6 Beta 4 signaling pathway | |||
27 | BDNF signaling pathway | |||
28 | Integrated Pancreatic Cancer Pathway | |||
29 | Oncostatin M Signaling Pathway | |||
30 | Corticotropin-releasing hormone | |||
31 | Interleukin-11 Signaling Pathway | |||
32 | AGE/RAGE pathway | |||
33 | TNF alpha Signaling Pathway | |||
34 | B Cell Receptor Signaling Pathway | |||
35 | Prostate Cancer | |||
36 | Signaling Pathways in Glioblastoma | |||
37 | TSLP Signaling Pathway | |||
38 | IL17 signaling pathway | |||
39 | IL-7 Signaling Pathway | |||
40 | Regulation of Microtubule Cytoskeleton | |||
41 | TWEAK Signaling Pathway | |||
42 | FSH signaling pathway | |||
43 | Leptin signaling pathway | |||
44 | TSH signaling pathway | |||
45 | RANKL/RANK Signaling Pathway | |||
46 | Integrated Breast Cancer Pathway | |||
47 | SREBP signalling | |||
48 | Integrated Cancer pathway | |||
49 | IL-1 signaling pathway | |||
50 | Metabolism of nitric oxide | |||
51 | Integrin-mediated Cell Adhesion | |||
52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
53 | MicroRNAs in cardiomyocyte hypertrophy | |||
54 | Angiogenesis | |||
55 | TOR Signaling | |||
56 | Regulation of toll-like receptor signaling pathway | |||
57 | AMPK Signaling | |||
58 | Androgen receptor signaling pathway | |||
59 | IL-5 Signaling Pathway | |||
60 | Monoamine Transport | |||
61 | SIDS Susceptibility Pathways | |||
62 | TGF Beta Signaling Pathway | |||
63 | Cytokines and Inflammatory Response | |||
64 | MAPK Signaling Pathway | |||
65 | EV release from cardiac cells and their functional effects | |||
66 | FAS pathway and Stress induction of HSP regulation | |||
67 | Transcriptional Regulation of White Adipocyte Differentiation | |||
68 | Aryl Hydrocarbon Receptor | |||
69 | Nanoparticle triggered regulated necrosis | |||
70 | Amyotrophic lateral sclerosis (ALS) | |||
71 | Adipogenesis | |||
72 | Allograft Rejection | |||
73 | Extrinsic Pathway for Apoptosis | |||
74 | Folate Metabolism | |||
75 | Vitamin B12 Metabolism | |||
76 | Selenium Micronutrient Network | |||
77 | Matrix Metalloproteinases | |||
78 | ErbB Signaling Pathway | |||
79 | Focal Adhesion | |||
80 | Bladder Cancer | |||
81 | Signaling by ERBB2 | |||
82 | miR-targeted genes in muscle cell - TarBase | |||
83 | Semaphorin interactions | |||
84 | IL1 and megakaryotyces in obesity | |||
85 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
86 | Activation of Matrix Metalloproteinases | |||
87 | Degradation of collagen | |||
88 | Spinal Cord Injury | |||
89 | Osteopontin Signaling | |||
90 | Type II interferon signaling (IFNG) | |||
91 | Senescence and Autophagy in Cancer | |||
92 | Myometrial Relaxation and Contraction Pathways | |||
93 | Aryl Hydrocarbon Receptor Pathway | |||
94 | Hematopoietic Stem Cell Differentiation | |||
95 | Alzheimers Disease | |||
96 | Interleukin-1 signaling | |||
97 | Serotonin Transporter Activity | |||
98 | NOD pathway |